Lumipulse® G TPOAb (Anti-Thyroid Peroxidase Antibodies)
Immunoreaction cartridges forin vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of Anti-Thyroid Peroxidase Antibodies (TPOAb) in serum or plasma. Includes calibrators.
The assay utilises proven CLEIA (ChemiLuminescent Enzyme Immunoassay) technology with results that are available in up to 35 minutes.
Product number 230572
Click here to navigate
- Details
- Conditions of sale
- Documentation
- FAQ
- Related products
- Product inquiry
-
Details
CLEIA - ChemiLuminescent Enzyme Immunoassay
Test principle: Two-Step sandwich assay
Clinical backgroundTPOAb
Thyroid autoantibodies appear mostly with the presence of lymphocytes in the targeted organ and Thyroid Peroxidase Antibodies is one of these autoantibodies.
These autoantibodies affect different targets in the thyroid gland, and although a healthy patient may be positive for this autoantibody, this does not mean that they will necessarily present with thyroid problems although they may have thyroid dysfunction over time.
The major antigen has been recently identified as thyroid peroxidase (TPO), which plays an important role in thyroid hormone synthesis.
Consequently, assay of the anti-thyroid peroxidase antibody (TPOAb) titer, instead of the anti-microsome antibody titer, has come to be used as a diagnostic marker of autoimmune thyroid disease.
See the LUMIPULSE G1200 working in this video:
-
Conditions of sale
To read the end user conditions of sale for this product please visit our Resource center.
-
Documentation
Browse regulatory documents for this product
Create a (free!) eServices account and start browsing all regulatory documentation right away.
Get access to this section and more
Create a free eServices account now and instantly access multiple digital resources:
- Regulatory product documentation
- Selected scientific posters
- Product leaflets
- How-to videos and more…
-
FAQ
How does the coronavirus disease Covid-19 impact Fujirebio's operations?
Please see the following statement on the impact of coronavirus disease Covid-19 on the operations of Fujirebio Europe (updated January 19, 2021).
-
Related products
-
Product inquiry